If you need to inquire about Bayer product, please contact us through the following telephone:

Hotline: 400-810-0360 (available by mobile or telephone)

We will try our best to provide you the information about Bayer products, but we can't propose any specific diagnosis and treatment suggestions for patients' conditions. If you have any discomfort after medication, please go to see your doctor and receive timely medical treatment.

If you want to report a side effect or quality complaint, please contact your health care professional (e.g. treating physician or pharmacist) or your local health authority, Inquiries can also be directed to:

If you observe adverse event after Bayer Animal Health product application, you can transfer the information to us directly by:

Bayer and WuXi Biologics enter into an agreement on a Leverkusen drug product plant

Leverkusen, January 16, 2020Bayer and WuXi Biologics (WuXi Bio) have entered into an agreement that WuXi Biologics Germany GmbH will take over operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building. Based on the manufacturing agreements to be negotiated, the WuXi Bio-operated plant shall serve as a back-up site for final product manufacturing of Kovaltry™ (antihemophilic factor (recombinant)), while Bayer’s drug substance and drug product facility in Berkeley, California, USA, will remain the major site for the manufacturing and filling of it. The transaction is expected to be concluded in the coming months subject to the satisfaction of customary closing conditions. Financial details were not disclosed.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. WuXi Bio‘s track record and achievements demonstrate its commitment to global clients by providing a ONE-stop service offering with strong value proposition. With biopharmaceutical production planned in China, Ireland, Germany, Singapore, and the U.S., WuXi Bio will provide their biomanufacturing partners with a robust and premier-quality global supply chain network. For more information, please visit

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Follow Us
Last updated:2020-06-01
XML 地图 | Sitemap 地图